Oncology therapeutics continue to lead FDA and EMA approvals year over year, with drug discovery services in oncology predicted to have a 15% CAGR this year. Regardless of your tumor type focus, or whether your therapeutic approach involves small molecules, antibody-drug conjugates (ADCs), or immunotherapies, Eurofins Discovery is your partner of choice.
We provide Integrated Drug Discovery solutions to help your journey from idea to IND. With a strong team of scientific experts and program managers, we work with you to design your oncology pathway to seamlessly increase your chance of success. Through this webinar, you’ll learn how we are addressing the challenges of oncology drug discovery and supporting programs with our 12,000+ in vitro assays, key services, and the tools needed to advance both monotherapies and combination approaches in the fight against cancer.
Key Learning Objectives:
- What are the key challenges in oncology drug discovery and how we are addressing them.
- How undruggable targets are being prosecuted.
- How clinical failure can be minimized due to unforeseen adverse events.
- The technologies and modalities that are transforming oncology drug discovery.
- How to understand your molecule’s mode of action and biological context prior to clinical testing.